Member Info for elrico

AT,

The order number question is on my list for a more in-depth update. I am confident the order numbers do not work the same way as OPTI online store does. However, I am not prepared to say how without getting this fact-checked.

I suspect Stuart will have this blocked by the NOMAD because it is commercially sensitive, so details may be limited because this sort of info is dangerous and left to investors to run riot with. lol

Raytheg and the other two blinkered shortsighted voting for you would apply basic commonsense and perhaps even a little research into what has already in the public domain; maybe you would come to the following conclusion.

1: My efforts appear timely
2: My readers have acted on my update and addressed a declining SP yesterday, which continues today
3: There is NOTHING in my update that is not already in the public domain - it is just a reiteration of known facts

Now apply your combined foolish logic and use it. Are you all seriously suggesting no company talks to any editor or analyst publishing behind a paywall?

This would mean no analyst/broker reports, be they to private clients (standard practice) or behind sites such as Research Tree, as an example. *************, Michael Walters etc., etc. It would close the door to a significant cottage industry designed to help a wide range of investors.

I would ask all you shortsighted investors to do some maths on your investments and calculate what you lost yesterday before my update and how much has been gained since? I bet you it's most likely worth more than a poxy £35.

I am aware I have my detractors, just as TW, MW, etc., have. I am also mindful of the tactics these people have. However, it demonstrates their folly and cares nothing for other investors. Using a public forum to bully Stuart and me into silence is foolish. He has a duty to shareholders, and I am responsible for my readers. As long as we follow the regulator's rules and regulations, including the NOMAD (think on this), all investors benefit, not just those that pay for my service. Are you so blind you do not see!!

There have been a lot of enquiries asking why they can’t receive their shares electronically via crest and why share certificates need to be issued? I have checked with the company and the registrars insisted on distributing the certs rather than transferring shares electronically via Crest as it is very easy for shares to go missing when transferring over Crest and very difficult to retrieve them and as such, the safest way is to send certificates.

Hope this helps.

There have been a lot of enquiries asking why they can’t receive their shares electronically via crest and why share certificates need to be issued? I have checked with the company and the registrars insisted on distributing the certs rather than transferring shares electronically via Crest as it is very easy for shares to go missing when transferring over Crest and very difficult to retrieve them and as such, the safest way is to send certificates.

Hope this helps.

Interactive stupidity. How many sold before reading the ii corporate message?

https://twitter.com/LEMMINGINVESTOR/status/1521561161484967936

Interactive stupidity. How many sold before reading the ii corporate message?

hTTps://twitter.com/LEMMINGINVESTOR/status/1521561161484967936

Aquae,

Sorry. I did not intend to imply you did not know about the consumer study. I was a tad clumsy with my wording.

I made no ref to the website wording.

There would have been a delay to Croft doing their admin work due to the corporate action. https://lemminginvestor.substack.com/p/poolbeg-pharma-plc-8e7?s=w

TC,

There is an element of truth in your "naivety with the market" comment. But, I would also add this is Stuart's first PLC gig as a CEO, and perhaps too much control by the NOMAD, as suggested to me by some investors that have been around the block. That said, it is the NOMAD's role. They have a job to do, and it is not to look after our investment but to keep the company honest.

Clio,

Thank you for your correct observations, as to my role. It is true I offer opinion-based commentary, which is my role. I try to do so by staying as close to the facts as possible, and sometimes it means reading between the lines, or as you point out, sometimes it is what Stuart does not say can be important.

I do get it wrong - more recently, I admitted I felt partly responsible for disappointing investors when I suggested we could get a Croda update around October or November. I genuinely expected one, but we did not. However, I never suggested this was a certainty based on discussions with Stuart, so, I did not mislead anyone.

Aquae,

The original plan was not a consumer study but a clinical study if the clinical study validated the IP. If so, the company could make specific claims within regulatory rules. So yes, for sure, AxisBiotix Ps claims are based on the clinical results because these would be based on science, not anecdotal consumer feedback, even though the feedback was backed by time-lapsed photo evidence.

I am thankful the company was nimble and ambitious enough to go with the consumer study and not wait for lab space for the clinical study.

New in-depth update on SBTX after reading some somewhat mind-numbing trolling observations and some genuine comments sent to me by more sensible investors. https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-a8f?s=w

Odysseus07,

I guess I will have to accept you are beyond help. Several investors have spent time attempting to assist you and correct your errors, and yet you continue to repeat the same errors. I will not waste any more time on you. I will consign you to the filter list.

I grant you that most people will see through stupid comments that demonstrate abysmal research and understanding of the company, its model, and what it takes to build revenues from a standing start. However, it is a worth rebuttal on occasions because there is always a newbie worthy of engaging. On this occasion, requesting the sacking of a CEO that has delivered on all but one of his goals (and he may still - I pray) and delivered exceptional returns for investors over the last three years deserves defending. I am sure some investors are losing money on their investment because they discovered the company much later than some of us. I feel for them right now, but I am confident sentiment will change once positive news from Croda/Sederma filters through. There is much to look forward to in this regard, and other projects are in the pipe. SBTX is not just AxisBiotix, but that seems to be where most people have been focused on since the TU.

Stuart has remarkable helpful to investors, and I am sure he will continue to help where he can.

Odysseus07,

Your comments do not support intelligent life!

You are an emotional investor struggling to control your angst and wish others to feel the same way as you do. However, suppose you cannot even understand the basics, such as the accounting period, trading statement period, and forecast period. In that case, you are very likely to continue to make foolish decisions throughout your investing life - it is a significant handicap.

"Guys, we don't know what material means",—ignoring your stupid comments. What I mean is relatively simple, and I suspect many investors capable of commonsense and understanding what constitutes a profit warning would understand the context of my comment. Typically, if a company believes it will miss its forecast by 20%>, it is duty-bound to issue a warning to the market. This is what material usually means. However, the absence of a replacement forecast leaves room for wild guesses, And foolish interpretations from people like yourself.

Suggesting Stuart should be sacked is another emotional outburst from someone that can't get the primary data correct. Had it not been for Stuart and his team's adaptability, the consumer study would not have been done, and therefore there would not be a commercial product. Therefore the company would be at least 2-3 years further down the road from a D2c product with another (Acne).

As for begrudging Stuart's salary, another foolish comment. Do you have any idea what a typical AIM CEO salary package is? I doubt you do. I am not going to tell you either. Try doing some research on the topic. You may be surprised.

I can count Stuart's mistakes on a single finger, and you want to sack him for agreeing to a forecast into the market! Therefore, I will not regurgitate what I said in my last comments on this topic.

You know SBTX's fortunes do not hang by the AxisBiotix Ps product, right!

Aqua and Toyin have hit the nail on the head.

Until the £1.2m was taken off the table just six weeks after it was stated it was achievable, Stuart had an unblemished record. The sad thing is, there are a lot of investors that companies have misled over time, and the fear for some is that SBTX is another. I do not believe Stuart or SBTX has misled. Stuart has followed the advice of the NOMAD, and it is after all that they are there for.

My reading of the situation after a lengthy chat is quite simple. It has taken a few weeks longer to get the marketing, influence, and customer service teams in place. I am sure it was expected this would be done earlier. However, they are now in place, and there is growing evidence that they are positively affecting interactions, which I believe are transferring into increased subscriptions. No, I do not have numbers. Stuart plays with a straight bat.

If I am honest, I think I may have unwittingly played a part in disappointing investors. I said I was hopeful for an update from Croda around November. This did not materialise. This was a misread from me and had NOTHING to do with Stuart priming me. I know that some investors were disappointed not to hear anything positive from Croda from my inbox. The fact everything is running to schedule is not good enough for some.

We know Sederma clients already have the lysate - this is excellent news because it means there is enough from the scale up to supply them. After that, it is a matter of waiting to see who moves first.

I am a little gutted because the wife has swapped the old sofa for a new one after someone on here complained I was constantly rummaging down the back for more funds. :)

There are signs the new staff are cracking up awareness. https://www.instagram.com/axisbiotix/

It may appear I am suggesting there could be a “permanent closed window”, but I am not. I am merely attempting to add to the discussion, which some repeat, often when the SP has been through a depressed period. It is as though some people think a CEO purchase is a magic fix. Anyone familiar with Cathal of ORPH will know he spent £300k at 27p; it did not halt the 50% decline on his purchase.

I was reminded of the following; There are two reasons a board member can’t buy; one during a close period is the period one month before the release of results. The second is if they have inside information that could materially impact the share price in the near term. This typically relates to agreements that have been signed by one or both parties, NOT to ongoing discussions or draft agreements with partners, which can continue for many months and years.

Would I like to see SBTX board members demonstrate confidence by adding to their position? Yes, of course. I prefer a board with added skin in the game and not rely on the remuneration package or share options. While I accept Stuart took a pay cut to take the role as CEO, he is paid an excellent salary. However, it is always one-way with retail investors. We always want to see the board buy but loath them to sell. One other point worth making. SA has SP performance-related options.

Perhaps Stuuart is thinking strategically.
Given the SP target/options, I am sure SA will want to avoid the accusation of SP manipulation to obtain his following options.

This may be of interest to the broader lithium market.

#ALL is featured in a separate editorial that looks at minors that are expected to play a significant role in the EV/Electric storage races.

https://knowledge.sharescope.co.uk/2022/04/08/small-company-champion-how-to-play-the-electric-vehicle-revolution/

Should read: Here are some clues why SA or any board member can not buy SBTX shares.

Oh, the old CEO buy chestnut! An insider is never a sideshow; it is a serious business. If it escaped your notice, 4 BOD members are classed as insiders. They will be privy to price-sensitive information; therefore, it is tricky to find an optimum window to buy. Should SA or the new CFO buy, you will likely be the first to say that there is no news soon and bail, hoping for a drift in the SP.

Here are some clues why SA or any board member can buy SBTX shares.

Current negotiations with distributors for EU launch
Negotiations are ongoing for a partner for oral care
Plus, whatever GB is dealing with
There could be news from Croda/Sederma in the pipe.

Apply reasonable logic, and you should see the folly of your case.